Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
Portfolio Pulse from
Palisade Bio, Inc. has received cash proceeds from Canada's SR&ED Tax Incentive Program to reimburse development costs for PALI-2108, a treatment for Ulcerative Colitis, developed in partnership with Giiant Pharma, Inc.
February 20, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palisade Bio, Inc. received funding from Canada's SR&ED Tax Incentive Program for the development of PALI-2108, a treatment for Ulcerative Colitis, in partnership with Giiant Pharma, Inc.
The receipt of funding from the SR&ED Tax Incentive Program is a positive development for Palisade Bio as it provides financial support for the development of PALI-2108. This can enhance the company's financial position and potentially accelerate the development process, which is beneficial for investors.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100